Viral Gastroenteritis Treatments

Find Viral Gastroenteritis Treatments

Generic Name

Infliximab

Brand Names

Avsola, Inflectra, Remicade, Renflexis, Zymfentra

FDA approval date: August 24, 1998

Classification: Tumor Necrosis Factor Blocker

Form: Injection, Kit

What is Avsola (Infliximab)?

AVSOLA is a tumor necrosis factor blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response

Who is this study for: Patients with early rheumatoid arthritis

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Drug: Methotrexate

Study Phase: Phase 3

Summary: Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure. Current treatment goals are to minimize pain, limit joint damage, and prevent loss of function. Drugs used to treat RA include non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids, and disease-modifying anti-rheumatic drugs (DMARDs), including biologics...

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Who is this study for: Adult patients with stroke, aneurysm, vasculitis, and tumor necrosis factor-alpha

Enrollment Status: Recruiting

Publish Date: June 11, 2026

Intervention Type: Drug

Study Drug: Infliximab

Study Phase: Phase 1/Phase 2

Summary: Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms

A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis

Enrollment Status: Recruiting

Publish Date: June 10, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: Immune-related colitis from immune checkpoint inhibitors (ICI) is a common adverse effect causing significant morbidity and impairment of quality of life (QoL). Steroids are the first line of treatment for severe ICI induced Immune- mediated diarrhea and colitis (IMDC). If there is no improvement in 48 to 72 hours, other immunosuppressive agents (infliximab, vedolizumab) are recommended. However, ...

View All Clinical Trials